1. Navigate to /scrip
  2. Navigate to /scrip/business
  3. Navigate to /scrip/business/financing

Sonoma Bio Raises $265m To Test T-regs In Autoimmune Diseases

First Indication Is RA, But IBD Is Another Opportunity

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The company will determine whether a single administration of autologous regulatory T-cells (Tregs) can reset and restore immune tolerance in autoimmune, inflammatory and neuroinflammatory diseases.

Young woman with rheumatoid arthritis deformed fingers
Sonoma Bio's T-reg therapies may offer a polypharmacy approach to treating rheumatoid arthritis and other autoimmune diseases • Source: Alamy

Sonoma Biotherapeutics revealed a $265m series B venture capital round on 4 August that will fund the first clinical trials of its autologous regulatory T-cell (Treg) therapies to test whether the company can deliver a one-time treatment with the ability to restore immune system balance in autoimmune diseases and inflammation, including neuroinflammation. Sonoma Bio’s lead Treg program is designed to treat rheumatoid arthritis, but it is also investigating Tregs for inflammatory bowel diseases.

In addition, the South San Francisco- and Seattle-based company is developing an effector T-cell (Teff)-depleting agent and plans to take...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.